Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Synthetic Lethality in Cancer Therapeutics: The Next Generation
Jeremy Setton, Michael Zinda, Nadeem Riaz, et al.
Cancer Discovery (2021) Vol. 11, Iss. 7, pp. 1626-1635
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Engineered cellular immunotherapies in cancer and beyond
Amanda Finck, Tatiana Blanchard, Christopher P. Roselle, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 678-689
Open Access | Times Cited: 208
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
David Gallo, Jordan T.F. Young, Jimmy Fourtounis, et al.
Nature (2022) Vol. 604, Iss. 7907, pp. 749-756
Open Access | Times Cited: 131
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
Zeid Kuzbari, Chaitanya Bandlamudi, Chey Loveday, et al.
Annals of Oncology (2022) Vol. 34, Iss. 3, pp. 215-227
Open Access | Times Cited: 71
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Muhammad Tufail, Canhua Jiang, Ning Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 54
A new wave of innovations within the DNA damage response
Qi Li, Wenyuan Qian, Yang Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 53
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A. Yap, Elisa Fontana, Elizabeth K. Lee, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1400-1411
Open Access | Times Cited: 50
DNA Damage and Its Role in Cancer Therapeutics
Jaeyoung Moon, Ichiwa Kitty, Kusuma Renata, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4741-4741
Open Access | Times Cited: 42
Targeting ATR in patients with cancer
Natalie Ngoi, Patrick G. Pilié, Daniel J. McGrail, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 278-293
Closed Access | Times Cited: 22
PARP Inhibitors for Breast Cancer Treatment
Stefania Morganti, Antonio Marra, Carmine De Angelis, et al.
JAMA Oncology (2024) Vol. 10, Iss. 5, pp. 658-658
Closed Access | Times Cited: 18
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Salomé Adam, Silvia Emma Rossi, Nathalie Moatti, et al.
Nature Cancer (2021) Vol. 2, Iss. 12, pp. 1357-1371
Closed Access | Times Cited: 78
Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs
Hussein Sabit, Mohamed Abdel-Hakeem, Tahsin Shoala, et al.
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1566-1566
Open Access | Times Cited: 55
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
Panieh Terraf, Fresia Pareja, David Brown, et al.
Annals of Oncology (2022) Vol. 33, Iss. 4, pp. 426-433
Open Access | Times Cited: 39
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 27
Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy
Daniela Spano, Giuliana Catara
Cells (2023) Vol. 13, Iss. 1, pp. 29-29
Open Access | Times Cited: 25
PD-1/PD-L1 and DNA Damage Response in Cancer
Mateusz Kciuk, Damian Kołat, Żaneta Kałuzińska‐Kołat, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 530-530
Open Access | Times Cited: 23
Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors
Giulia Giacomini, Sandra Piquet, Odile Chevallier, et al.
Nucleic Acids Research (2024) Vol. 52, Iss. 5, pp. 2372-2388
Open Access | Times Cited: 13
Cell death pathways: molecular mechanisms and therapeutic targets for cancer
Shaohui Wang, Sa Guo, Jing Guo, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 12
A systematic analysis of the landscape of synthetic lethality-driven precision oncology
Alejandro A. Schäffer, Youngmin Chung, Ashwin V. Kammula, et al.
Med (2024) Vol. 5, Iss. 1, pp. 73-89.e9
Open Access | Times Cited: 11
CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine
Dilip Kumar Chanchal, Jitendra Singh Chaudhary, Pushpendra Kumar, et al.
Current Gene Therapy (2024) Vol. 24, Iss. 3, pp. 193-207
Closed Access | Times Cited: 10
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
Cai-Jin Lin, Xi Jin, Ding Ma, et al.
Cancer Cell (2024) Vol. 42, Iss. 4, pp. 701-719.e12
Closed Access | Times Cited: 8
Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma
Bo Zhang, Hui Peng, Mi Zhou, et al.
Cancer Research (2022) Vol. 82, Iss. 13, pp. 2388-2402
Open Access | Times Cited: 37
Guiding ATR and PARP inhibitor combinations with chemogenomic screens
Michal Zimmermann, Cynthia Bernier, Beatrice Kaiser, et al.
Cell Reports (2022) Vol. 40, Iss. 2, pp. 111081-111081
Open Access | Times Cited: 37
DNA repair as a shared hallmark in cancer and ageing
Thomas L. Clarke, Raúl Mostoslavsky
Molecular Oncology (2022) Vol. 16, Iss. 18, pp. 3352-3379
Open Access | Times Cited: 31
Computational methods, databases and tools for synthetic lethality prediction
Jing Wang, Qinglong Zhang, Junshan Han, et al.
Briefings in Bioinformatics (2022) Vol. 23, Iss. 3
Open Access | Times Cited: 29
Intratumor Heterogeneity and Treatment Resistance of Solid Tumors with a Focus on Polyploid/Senescent Giant Cancer Cells (PGCCs)
Razmik Mirzayans, David Murray
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11534-11534
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top